Kite Pharma: Focused on the Cure. Arie Belldegrun, MD, FACS Chairman, President, & Chief Executive Officer
|
|
- Tamsin Butler
- 6 years ago
- Views:
Transcription
1 Kite Pharma: Focused on the Cure Arie Belldegrun, MD, FACS Chairman, President, & Chief Executive Officer
2 Forward Looking Statements/Safe Harbor To the extent statements contained in this presentation are not descriptions of historical facts regarding Kite Pharma, Inc. ( Kite, we, us, or our ), they are forward-looking statements reflecting management s current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry s actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as anticipate, believe, could, estimate, expect, intend, may, plan, potential, predict, project, should, will, would or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) the ability and willingness of the National Cancer Institute (NCI) to continue research and development activities relating to our product candidates; (iii) our ability to obtain and maintain regulatory approval of KTE-C19 and any other product candidates; (iv) our ability to further develop and commercialize our product candidates; (v) our plans to research, discover and develop additional product candidates, including through our subsidiary Kite Pharma EU, and next generation product candidates, including a next-generation CAR with an on/off switch; (vi) our and our partners ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process; (vii) the size and growth potential of the markets for our product candidates, and our ability to serve those markets; (viii) the rate and degree of market acceptance of our product candidates; (ix) our ability to attract and retain key scientific or management personnel; (x) the anticipated timing of clinical data availability; (xi) the anticipated timing of commercial launch of KTE-C19; (xii) our plans to expand geographically; (xiii) our ability to meet the milestones set forth herein and (xiv) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission (SEC), including without limitation in its Quarterly Report on Form 10- Q filed with the SEC on May 9, Except as required by law, we undertake no obligation to publicly update any forwardlooking statements, whether as a result of new information, future events or otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 2
3 Kite: Focused on the Cure 3 Changing Empowering Utilizing Advancing Optimizing Building the paradigm of cancer treatment a patient s own immune system to combat cancer two technology platforms to address both hematologic and solid tumors our lead product candidate in four pivotal studies and preparing for 2017 commercial launch and automating in-house manufacturing to bring cell therapies to the broad market a pipeline of future cancer therapies with innovative internal R&D and collaborations with select industry leaders
4 Developing The Ultimate Personalized Cancer Immunotherapy ENGINEERED AUTOLOGOUS CELL THERAPY (eact ) Apheresis Manufacturing Process Infusion 4
5 Dual Platform Targets Both Hematological and Solid Cancers Chimeric Antigen Receptor (CAR) Targets molecules on the cell surface T Cell Receptor (TCR) Targets molecules at or below the cell surface 5
6 Kite Pharma: An Industry Leading Pipeline of CAR and TCR Product Candidates CHIMERIC ANTIGEN RECEPTOR (CAR) PRE-IND PHASE 1 PHASE 2 KTE-C19 DLBCL, PMBCL, TFL (ZUMA-1) T CELL RECEPTOR (TCR) PRE-IND PHASE 1 PHASE 2 MAGE A3/A6 Solid tumors KTE-C19 MCL (ZUMA-2) MAGE A3 Solid tumors KTE-C19 Adult & Pediatric ALL (ZUMA-3, ZUMA-4) KTE-C19 2 nd Wave of ZUMA Studies Combination, FL, CLL Human Anti-CD19 Heme malignancies Amgen Multi-Target Collaboration Heme malignancies Amgen Multi-Target Collaboration Solid tumors HPV-16 E6 Cervical and head & neck cancer HPV-16 E7 Cervical and head & neck cancer NY-ESO-1 Solid tumors SSX2 Solid tumors KRAS KRAS mutation tumors NEO-ANTIGENS Solid tumors 6 DLBCL = diffuse large B cell lymphoma PMBCL = primary mediastinal B cell lymphoma TFL = transformed follicular lymphoma MCL = mantle cell lymphoma ALL = acute lymphoblastic leukemia FL = follicular lymphoma CLL = chronic lymphocytic leukemia
7 Kite: Investigating Targets with Broad Clinical Applicability CD19 Non-Hodgkin Lymphoma Leukemias Kite Targets from Amgen Collaboration AML MM Kidney Lung CARs TCRs MAGE A3/A6 NY-ESO-1 HPV-16 E6/E7 SSX2 KRAS Neo-Antigens Lung Pancreatic Gastric Cervical Head & Neck Anal Cancer Urothelial Sarcoma Lung HCC Melanoma Prostate Pancreatic CRC Lung Potentially all types of cancer Breast Melanoma Sarcoma 7
8 Executive Management and Scientific Team Have a Proven Track Record of Success Arie Belldegrun, MD, FACS Chairman, President and CEO Cynthia M. Butitta Chief Operating Officer Paul Jenkinson Chief Financial Officer David D. Chang, MD, PhD EVP R&D, Chief Medical Officer Shawn C. Tomasello Chief Commercial Officer Tim Moore EVP, Technical Operations Helen S. Kim EVP, Business Development Margo R. Roberts, PhD Chief Scientific Officer Jeff Wiezorek, MD, MS SVP, Clinical Development Executive Management Chiron Owen N. Witte, MD (Chairman) UCLA Scientific Advisory Board James Allison, PhD The University of Texas MD Anderson Cancer Center James Economou, MD, PhD UCLA Zelig Eshhar, PhD Tel Aviv Sourasky Medical Center & Weizmann Institute of Science Donald Kohn, MD UCLA Ton N. M. Schumacher, PhD Chief Scientific Officer Ronald Levy, MD Stanford School of Medicine Antoni Ribas, MD, PhD UCLA Padmanee Sharma, MD, PhD The University of Texas MD Anderson Cancer Center Inder Verma, PhD The Salk Institute Special Advisor Steven A. Rosenberg, MD, PhD NCI/KITE CRADA Kite Pharma EU 8
9 Leveraging Academic and Industry Collaborations for Next Generation Technologies Strategic Collaborations Surgery Branch Experimental Transplantation & Immunology Branch TCR Enabling Technologies CAR 9
10 Significant Accomplishments Initiated four KTE-C19 pivotal studies in DLBCL, MCL, adult, and pediatric ALL under two separate company INDs Received Breakthrough Therapy Designation for KTE-C19 under company IND in the US and PRIME Designation in the EU Secured Orphan Drug Designation for KTE-C19 in the US and EU for all our hematological indications Established European operations with T-Cell Factory acquisition, NKI agreement and launched Kite EU Built out the company with the addition of over 100 new hires, including the Chief Commercial Officer and EVP of Technical Operations 10
11 11 DELIVER IN HEMATOLOGY Four pivotal studies for KTE-C19 Second wave of KTE- C19 studies Commercial launch of KTE-C19 in 2017 planned FOCUS ON SOLID TUMORS 2016 IND for MAGE A3 CAR product candidates from Amgen collaboration TCR GENErator TM technology for additional TCR product candidates DEVELOP NEXT GEN. CELL THERAPY Combination therapy (Genentech) Modulating immune synapse using the vigd technology (Alpine IS) Fully automated process (GE Global Research) Building the Future of Cancer Therapy
12 Introducing Control to CAR through Synthetic Biology A SPLIT CAR design that allows for a DIALABLE, INSTANT, and, REVERSIBLE control of CAR activity, in the presence of a small molecule scfv, single-chain variable fragment; TCR, T cell receptor; ITAM, immunoreceptor tyrosine-based activation motif 32
13 Ongoing ZUMA Studies to Support Registration of KTE-C19 Study Phase Indication Status ZUMA-1 ZUMA-2 ZUMA-3 ZUMA-4 Phase 2 Pivotal (N=112) Phase 2 Pivotal (N=70) Phase 1/2 Pivotal (N=75) Phase 1/2 Pivotal (N=75) DLBCL PMBCL TFL MCL Adult ALL Pediatric ALL Additional studies in FL, CLL, earlier lines of DLBCL, and combination studies starting in 2016 Enrolling Interim Data * 2016 Primary Data 2017 Enrolling Data 2017 Phase 1/2 Enrolling P2 Data 2017 Phase 1/2 Enrolling P2 Data *If supported by data, plan to file Biologics License Application based on interim data
14 KTE-C19 Will Address Largest Unmet Need in NHL Incidence per year US new cases per year US deaths per year 26,000 15,700 10,000 4,600 6,000 1,400 DLBCL CLL ALL 14 *Ex-US incidence of DLBCL is 24,000 cases per year (France, Germany, Italy, Spain, UK, and Japan)
15 ZUMA-1 Phase 1 Clinical Data Show Ongoing CRs at 9-Month Follow-Up Efficacy 71% Objective Response Rate (n=5/7) 57% Complete Remissions (n=4/7) 3 Complete Remissions ongoing at 9 months Safety 1 patient with DLT (grade 4 CRS and neurotoxicity) died on study (unrelated to KTE-C19) 14% grade 3+ CRS 57% grade 3+ neurotoxicity With the exception of the patient with DLT, all grade 3 KTE-C19-related toxicities resolved Baseline Complete Response at Day 30 Neelapu et al, ASCO Annual Meeting
16 SCHOLAR-1: the first and largest patient-level meta-analysis of chemorefractory DLBCL SCHOLAR-1 is a retrospective analysis of 635 patients with chemorefractory DLBCL from 4 studies/institutions Patients with chemorefractory DLBCL have consistently poor outcomes regardless of refractory subgroup, line of therapy, and disease stage These data provide a historical benchmark for future studies in chemorefractory DLBCL Overall response rate 26% (18% PR & 8% CR) Median OS 6.6 months 17
17 NCI Data Demonstrating Breakthrough Efficacy in Aggressive NHL Group (n) Best Response ORR CR All Patients (41)* 78% 54% All Aggressive NHL (27) 70% 48% Aggressive NHL with low dose conditioning regimen (19) ** 68% 47% Aggressive NHL with low dose conditioning regimen and Kite manufacturing process (13) 69% 54% Generally reversible CAR-related grade 3-4 AEs CRS: All patients 30%, Kite manufacturing 31% Neurotoxicity: All patients 44%, Kite manufacturing 69% **All CRs (9) are still in CR *8 patients converted from PR to CR Data as of 11/30/15 Data from ASCO
18 DLBCL Patient 38 With an Ongoing CR That Had Progressed on R-ICE, GDP, and R-EPOCH Before treatment 10 months after treatment Before treatment 10 months after treatment 18 18
19 Manufacturing On Track for KTE-C19 Launch in 2017 In-house clinical manufacturing in full operation Commercial facility in close proximity to LAX airport Capacity to produce 4,000-5,000 patient therapies per year Modular design is scalable and cost effective Site to produce KTE-C19 and all TCR products 19
20 9 4 Ongoing Registration Studies in >40 Sites
21 TCRs Have the Potential to Access a Broad Spectrum of Therapeutic Tumor Targets Potential CAR Targets (~27% Human Proteome) Potential TCR Targets (All Human Proteome) 21
22 Proof of Concept for MAGE A3 TCR and HPV TCR PR: 85% Tumor Reduction Cervical Cancer Patient 100% Tumor Disappearance Pre-Treatment MAGE A3 is expressed in NSCLC, bladder, myeloma, SCC, melanoma, among others 3 responders (cervical, esophageal, and urothelial cancer) among 14 evaluable patients No off-target toxicities 12 Months HLA-DPB1*0401 present in 40% to 70% of Caucasian population Pre-Treatment 15 Months HPV infection is associated with 5% of all cancers globally Durable CR (22+ months) in cervical cancer patients treated with HPV reactive T cell therapy 1 HPV-16 E6 TCR Phase 1 study at NCI showed a significant response (-90%) in a patient with anal cancer HLA-A*0201 is present in 40% of the total US population 22 Lu, YCW, AACR Annual Meeting Stevanovic, 2015, J Clin Onc epub
23 Innovating the Next Generation of Products Target Selection Validate Target Selectivity Advance Cancer-Specific Targets CAR/TCR Optimization Improve Target Fidelity of CAR/TCR Constructs Modulate CAR/TCR Function in vivo Reduce Immunogenicity Manufacturing Automate Manufacturing Selectively Expand Potent T Cell Subsets ex vivo Tumor Microenvironment Overcome Immune Suppression Combination Therapy Introduce Gene Editing or Gene Modulation Clinical Development Optimize in vivo T Cell Expansion Improve Safety Management Identify Predictive Biomarkers for Safety and Efficacy 23
24 2016 Projected Milestones Report interim data for Phase 2 ZUMA-1 File KTE-C19 BLA on interim data Complete qualification/validation of manufacturing facility Initiate KTE-C19 clinical studies in Europe Initiate Phase 1b/2 combination study of Kite s KTE-C19 and Genentech s atezolizumab File IND for first Kite TCR product: MAGE A3 25
25 Kite: Focused on the Cure 25 Changing Empowering Utilizing Advancing Optimizing Building the paradigm of cancer treatment a patient s own immune system to combat cancer two technology platforms to address both hematologic and solid tumors our lead product candidate in four pivotal studies and preparing for 2017 commercial launch and automating in-house manufacturing to bring cell therapies to the broad market a pipeline of future cancer therapies with innovative internal R&D and collaborations with select industry leaders
Tumor Antigens in the Age of Engineered T cell Therapies
Tumor Antigens in the Age of Engineered T cell Therapies September 30 th 2016 ESMO Preceptorship Course Amsterdam Carsten Linnemann, PhD Senior Scientist Kite Pharma EU B.V. Amsterdam Forward Looking Statements/Safe
More informationJefferies Global Healthcare Conference June 2, 2015
Jefferies Global Healthcare Conference June 2, 2015 Forward Looking Statements / Safe Harbor To the extent statements contained in this presentation are not descriptions of historical facts regarding Kite
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationCorporate Deck JP Morgan January 2019
Corporate Deck JP Morgan 2019 January 2019 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationThe Next Generation of Immunotherapy Platforms. 36 th Annual J.P. Morgan Healthcare Conference January 2018
The Next Generation of Immunotherapy Platforms 36 th Annual J.P. Morgan Healthcare Conference January 2018 Forward-Looking Statements This presentation contains certain forward-looking information about
More informationTransforming science into medicine
Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and
More informationActinium Pharmaceuticals, Inc.
, Inc. Actimab-A MRD Consolidation Strategy in MRD+ AML July 10, 2018 1 Disclaimer and Safe Harbor Some of the information presented herein may contain projections or other forward-looking statements regarding
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationPharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765
Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationCorporate Presentation
Corporate Presentation June 2017 Forward-Looking Statements This presentation contains forward-looking statements reflecting management s current beliefs and expectations. These forward looking statements
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationTargeting the Tumor Locally
ARMING THE IMMUNE SYSTEM TO FIGHT CANCER Targeting the Tumor Locally October 2017 NASDAQ:ONCS Cautionary Note Regarding Forward-Looking Statements To the extent statements contained in the following presentations
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationTransforming patients lives through cellular immunotherapy. Next Generation Cellular Immunotherapy June 2017
Transforming patients lives through cellular immunotherapy Next Generation Cellular Immunotherapy June 2017 1 Overview of Cell Medica Mission: Transform the treatment of cancer with cellular immunotherapy
More informationCorporate Presentation June Curis, Inc All Rights Reserved
Corporate Presentation June 2018 Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationPath to Value and Profitability
Path to Value and Profitability June 4, 2015 Tim Clackson, Ph.D. President of R&D, Chief Scientific Officer ARIAD Pharmaceuticals, Inc. Elsa So Non-small cell lung cancer ARIAD clinical trial patient Some
More informationCompany presentation. Claudio Bordignon, Chairman and CEO. Jefferies Global Healthcare Conference New York, 7 June 2012
Company presentation Claudio Bordignon, Chairman and CEO Jefferies Global Healthcare Conference New York, 7 June 2012 Forward-looking statements The presentation contains certain forward-looking statements.
More informationCytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer
November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationChimeric Antigen Receptor - CAR T cell therapy. Frederick L. Locke, MD 2/17/2017
Chimeric Antigen Receptor - CAR T cell therapy Frederick L. Locke, MD 2/17/2017 T cells are immune system cells that normally fight infection Each T cell recognizes a specific target T cells multiply and
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationState of the art: CAR-T cell therapy in lymphoma
State of the art: CAR-T cell therapy in lymphoma 14 th annual California Cancer Consortium conference Tanya Siddiqi, MD City of Hope Medical Center 8/11/18 Financial disclosures Consultant for Juno therapeutics
More information2018 Bank of America Merrill Lynch Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE 2018 Bank of America Merrill Lynch Healthcare Conference May 16, 2018 Forward-Looking Statements and Adjusted Financial Information
More informationQuarterly Update & ASH 2017 Abstract Conference Call
Quarterly Update & ASH 2017 Abstract Conference Call November 1, 2017 Nasdaq : BLUE 1 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationDISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL
DISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL Annual General Meeting 24 April 2018 Björn Frendéus, Acting CEO & CSO 1 IMMUNOTHERAPY HAS TRANSFORMED
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationAnnual Results 2017 & Business Update 13 April 2018
Annual Results 2017 & Business Update 13 April 2018 1 Disclaimer These slides and the accompanying oral presentation contain forward-looking statements and information. Forward-looking statements are subject
More informationPersonalized Therapeutics The Power of Epigenetics. Company Overview. June 2014
Personalized Therapeutics The Power of Epigenetics Company Overview June 2014 2013 Accomplishments Forward Looking Statements This presentation contains forward-looking statements that involve substantial
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationBackground. Outcomes in refractory large B-cell lymphoma with traditional standard of care are extremely poor 1
2-Year Follow-Up and High-Risk Subset Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma Abstract 2967 Neelapu SS, Ghobadi A, Jacobson
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationA Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions
A Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions Second Quarter 2017 Company Update and Financial Results July 31, 2017 2 Forward-Looking Statements This presentation
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationCelyad s CAR-T NKR-2 Program. Conference Call Presentation Wednesday, December 7 th :00pm CET / 8:00am EST
Celyad s CAR-T NKR-2 Program Conference Call Presentation Wednesday, December 7 th 2016 2:00pm CET / 8:00am EST Forward Looking Statements In addition to historical facts or statements of current condition,
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015
ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM
More informationMerck Pipeline. November 1, 2017
Merck Pipeline November 1, 2017 Lead-in Language The chart below reflects the Company s research pipeline as of November 1, 2017. Candidates shown in Phase 3 include specific products and the date such
More informationINTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution
More informationChildren s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant
Children s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant Reporting Period January 1, 2012 June 30, 2012 Formula Grant Overview The Children s Hospital of Philadelphia received $3,521,179
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationCorporate Overview NASDAQ: CLRB
Corporate Overview NASDAQ: CLRB Safe Harbor Statement 2 This presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationN a s d a q : I N S Y
N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations
More informationScience, patient benefits and productivity
Science, patient benefits and productivity Alan Hippe, CFO Roche Group London, November 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More information8 of 21 (38.1%) Achieved RECIST v1.1 Durable Complete Response (CR) in Predicted Anti-PD-1 Non-Responder Melanoma Patients at 24 Weeks
October 19, 2017 OncoSec Presents Positive Phase 2 Data for ImmunoPulse IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non- Responder
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationIMMUNOTHERAPY IMMUNOTHERAPY. 37th Annual JPMorgan Healthcare Conference
NEXT-GENERATION NEXT GENERATION ONCOLYTIC ONCOLYTIC IMMUNOTHERAPY IMMUNOTHERAPY 37th Annual JPMorgan Healthcare Conference 2 Safe harbor Any statements contained herein that are not statements of historical
More informationMerck Oncology Overview ASCO 2017
Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking
More information